Results 341 to 350 of about 3,864,754 (383)

Emergency Medical Services Utilization during an Outbreak of Severe Acute Respiratory Syndrome (SARS) and the Incidence of SARS‐associated Coronavirus Infection among Emergency Medical Technicians

open access: green, 2004
Patrick Chow‐In Ko   +8 more
openalex   +1 more source

Role of the DPP4 Receptor in SARS‐CoV Entry: Insights From Docking and Molecular Dynamics Simulations

open access: yesProteins: Structure, Function, and Bioinformatics, EarlyView.
ABSTRACT Protein–receptor interactions play a critical role in viral entry and pathogenesis. While ACE2 is the primary receptor for SARS‐CoV, the role of DPP4 as potential coreceptor remains underexplored. This study investigates the binding mechanisms and dissociation dynamics of the SARS‐CoV/DPP4, SARS‐CoV/ACE2 and MERS‐CoV/DPP4 complexes using ...
Patrícia Pereira Duzi Carvalho   +1 more
wiley   +1 more source

Fungal metabolite 6-pentyl-α-pyrone reduces canine coronavirus infection. [PDF]

open access: yesHeliyon
Cerracchio C   +6 more
europepmc   +1 more source

Disease–Drug–Drug Interaction of Imatinib in COVID‐19 ARDS: A Pooled Population Pharmacokinetic Analysis

open access: yesCPT: Pharmacometrics &Systems Pharmacology, Volume 14, Issue 3, Page 583-595, March 2025.
ABSTRACT Prior pharmacokinetic (PK) analysis revealed that increased alpha‐1‐acid glycoprotein (AAG) levels are associated with decreased imatinib unbound fraction in coronavirus disease 2019 (COVID‐19) patients. This study aimed to investigate the PK of total and unbound concentrations of imatinib and the metabolite N‐desmethyl imatinib in ...
Medhat M. Said   +10 more
wiley   +1 more source

Significance of Hypoalbuminemia in the Development of Thromboembolic Complications in Severe Cases of SARS-CoV-2 Coronavirus Infection. [PDF]

open access: yesJ Clin Med Res
Tarzimanova A   +11 more
europepmc   +1 more source

Efficacy and safety of anifrolumab across organ domains of systemic lupus erythematosus: A systematic review and meta‐analysis

open access: yesRheumatology &Autoimmunity, EarlyView.
A systematic review and meta‐analysis were conducted to review all clinical trial results of anifrolumab for treating systemic lupus erythematosus. Fourteen studies were included comprising 1322 patients and five studies were meta‐analyzed. It was found that anifrolumab 300 mg IV led to clinical improvement across composite lupus scores, cutaneous ...
Yomna W. Mahmoud   +11 more
wiley   +1 more source

Home - About - Disclaimer - Privacy